News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Curi Bio and Cook MyoSite Form Strategic Partnership to Advance Muscle and Metabolic Disease Research
Thursday, May 01, 2025Curi Bio a global provider of human D engineered tissue platforms has entered into a strategic partnership with Cook MyoSite a company specialising in skeletal musclebased therapies The collaboration aims to develop advanced human tissue
Er-Kim Signs Exclusive Agreement with Puma Biotechnology to Distribute NERLYNX® for Breast Cancer in Eastern Europe and Central Asia
Thursday, May 01, 2025ErKim a pharmaceutical company focused on introducing innovative therapies across the EMEA region has signed an exclusive distribution agreement with Puma Biotechnology Inc NASDAQ PBYI Under this agreement
Addex Signs Agreement with Sinntaxis for Exclusive Rights to mGlu5 Inhibitors in Brain Injury Recovery
Wednesday, April 30, 2025Addex Therapeutics a clinicalstage biopharmaceutical company listed on SIX and NASDAQ has entered into an option and collaboration agreement with Sinntaxis AB for exclusive rights to use intellectual property related to the treatment
Sandoz signs global licensing agreement with Henlius to commercialise biosimilar ipilimumab for oncology use
Wednesday, April 30, 2025Sandoz a global leader in generic and biosimilar medicines has entered a worldwide collaboration and licensing agreement with Shanghai Henlius Biotech Inc Henlius to commercialise a biosimilar version of ipilimumab a widely used oncology therapy
CHMP Recommends Approval of Fixed-Duration Calquence-Based Regimens for Untreated Chronic Lymphocytic Leukaemia in the EU
Tuesday, April 29, 2025AstraZenecas Calquence acalabrutinib in combination with venetoclax with or without obinutuzumab has been recommended for approval in the European Union for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia CLL
CSL Vifor and Travere Therapeutics Receive Full EU Approval for FILSPARI® in IgA Nephropathy
Tuesday, April 29, 2025CSL Vifor and Travere Therapeutics Inc have announced that the European Commission has granted full marketing authorisation for FILSPARI sparsentan to treat adults with primary IgA nephropathy IgAN who have a urine protein excretion
Ferrer Signs Strategic Collaboration with Prilenia for the Co-Development and Commercialisation of Pridopidine
Monday, April 28, 2025Ferrer an international pharmaceutical company focusing on rare neurological diseases has entered into a strategic collaboration with Prilenia Therapeutics BV a clinicalstage biotech company Under the terms of the agreement
Ray Therapeutics Receives $8 Million CIRM Grant to Support Gene Therapy for Retinitis Pigmentosa
Friday, April 25, 2025Ray Therapeutics a biotechnology firm focused on optogenetic gene therapies for vision restoration has secured an million grant from the California Institute for Regenerative Medicine CIRM The funding will aid in the clinical advancement of RTx an e...
Orphan Therapeutics Accelerator Forms Key Partnerships to Support Ultra-Rare Disease Treatments
Thursday, April 24, 2025The Orphan Therapeutics Accelerator OTXL a nonprofit biotechnology organisation dedicated to completing development and bringing treatments for ultrarare diseases to market has announced a series of new partnerships
Boehringer Ingelheim and Tessellate Bio Form Partnership to Develop Targeted Cancer Treatments
Wednesday, April 23, 2025Boehringer Ingelheim has entered into a research collaboration and global licensing agreement with Tessellate Bio a precision oncology company The partnership aims to develop firstinclass oral treatments for cancers that are difficult to treat
